López-Nevado Marta, Docampo-Cordeiro Jorge, Ramos José T, Rodríguez-Pena Rebeca, Gil-López Celia, Sánchez-Ramón Silvia, Gil-Herrera Juana, Díaz-Madroñero María J, Delgado-Martín María A, Morales-Pérez Pablo, Paz-Artal Estela, Magerus Aude, Rieux-Laucat Frederic, Allende Luis M
Immunology Department, University Hospital 12 de Octubre, Madrid, Spain.
Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
Front Immunol. 2021 Apr 29;12:656356. doi: 10.3389/fimmu.2021.656356. eCollection 2021.
Autoimmune lymphoproliferative syndrome (ALPS) is a primary immune regulatory disorder clinically defined by chronic and benign lymphoproliferation, autoimmunity and an increased risk of lymphoma due to a genetic defect in the FAS-FASL apoptotic pathway. Genetic defects associated with ALPS are germinal and somatic mutations in gene, in addition to germinal mutations in and genes. The accumulation of CD3+TCRαβ+CD4-CD8- double negative T-cells (DNT) is a hallmark of the disease and 20-25% of ALPS patients show heterozygous somatic mutations restricted to DNT in the gene (ALPS-sFAS patients). Nowadays, somatic mutations in the gene are detected through Sanger sequencing in isolated DNT. In this study, we report an ALPS-sFAS patient fulfilling clinical and laboratory ALPS criteria, who was diagnosed through NGS with a targeted gene panel using DNA from whole blood. Data analysis was carried out with Torrent Suite Software and variant detection was performed by both germinal and somatic variant caller plugin. The somatic variant caller correctly detected other six ALPS-sFAS patients previously diagnosed in the authors' laboratories. In summary, this approach allows the detection of both germline and somatic mutations related to ALPS by NGS, avoiding the isolation of DNT as the first step. The reads of the somatic variants could be detected even in patients with DNT in the cut off limit. Thus, custom-designed NGS panel testing may be a faster and more reliable method for the diagnosis of new ALPS patients, including those with somatic mutations (ALPS-sFAS).
自身免疫性淋巴细胞增生综合征(ALPS)是一种原发性免疫调节障碍,临床上表现为慢性良性淋巴细胞增生、自身免疫以及由于FAS - FASL凋亡途径的基因缺陷导致淋巴瘤风险增加。与ALPS相关的基因缺陷包括 基因的胚系和体细胞突变,以及 基因和 基因的胚系突变。CD3 + TCRαβ + CD4 - CD8 - 双阴性T细胞(DNT)的积累是该疾病的一个标志,20 - 25%的ALPS患者在 基因中表现出仅限于DNT的杂合体细胞突变(ALPS - sFAS患者)。目前,通过桑格测序在分离的DNT中检测 基因的体细胞突变。在本研究中,我们报告了一名符合临床和实验室ALPS标准的ALPS - sFAS患者,该患者通过使用全血DNA的靶向基因panel进行二代测序(NGS)被诊断。使用Torrent Suite软件进行数据分析,并通过胚系和体细胞变异调用插件进行变异检测。体细胞变异调用插件正确检测出了作者实验室之前诊断的其他6名ALPS - sFAS患者。总之,这种方法允许通过NGS检测与ALPS相关的种系和体细胞突变,避免了将分离DNT作为第一步。即使在DNT处于临界值的患者中也能检测到体细胞变异的读数。因此,定制设计的NGS panel检测可能是诊断新的ALPS患者(包括那些有体细胞 突变的患者(ALPS - sFAS))的一种更快、更可靠的方法。